• Latest Posts

67% five-year survival rate in glioblastoma therapy, according to CANbridge Pharmaceuticals study

Likang gets trial ok for China’s first personalized cancer vaccine 

Could changing mRNA provide a new target for Alzheimer’s disease?

Porton and DanausGT look to boost development of gene and cell therapy

Biocytogen launches nanobody therapeutics project for 100 targets

ADVERTISEMENT

HKUMed uncovers T cell exhaustion factor driving cancer immunotherapy resistance

Lifesciences and biotech in 2023

Cartherics granted first patent in China

Legend Biotech new drug application approved in China

Jacobio’s cancer treatment given breakthrough therapy designations by China CDE

First subject dosed in inflammation phase I study

ADVERTISEMENT